Rhythm Pharmaceuticals/RYTM

$46.03

-0.26%
-
1D1W1MYTD1YMAX

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS); or Bardet-Biedl syndrome (BBS). It is evaluating setmelanotide in Phase II and III trials for the treatment of obesity due to variants in one of numerous genes associated with the MC4R pathway.

Ticker

RYTM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

David Meeker

Employees

177

Headquarters

Boston, United States

RYTM Metrics

BasicAdvanced
$2.67B
Market cap
-
P/E ratio
-$3.26
EPS
1.91
Beta
-
Dividend rate

What the Analysts think about RYTM

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 9 analysts.
27.94% upside
High $80.00
Low $49.00
$46.03
Current price
$58.89
Average price target

RYTM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-196% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$22.5M
17.19%
Net income
$-44.1M
-5.57%
Profit margin
-196%
-19.41%

RYTM Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 2.78%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q1 24
Actual
-$0.92
-$0.82
-$0.76
-
Expected
-$0.90
-$0.79
-$0.74
-$2.09
Surprise
1.71%
3.16%
2.78%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Rhythm Pharmaceuticals stock

Buy or sell Rhythm Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing